Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/04/2022* -- Results Q3 2022 -- -0.44 --
11/04/2022* 17:00 EST Earnings Call Q3 2022 -- -- --
08/04/2022 -- Results Q2 2022 -0.85 -1.02 16.38%
08/04/2022 17:00 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 -0.49 -0.67 26.60%
02/28/2022 -- Results Q4 2021 -0.79 -0.80 1.29%
02/28/2022 17:00 EST Earnings Call Q4 2021 -- -- --
11/04/2021 -- Results Q3 2021 -0.70 -0.81 13.18%
*Estimated Date/Time

Earnings

Next Report Date 11/04/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since 6.56%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
URL https://www.nektar.com
Investor Relations URL https://ir.nektar.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
8.71%
-27.18%
386.7%
-44.96%
-34.33%
-21.24%
-20.53%
-65.14%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-12.72%
-17.51%
-57.14%
272.4%
-50.90%
95.31%
-10.93%
102.7%
56.57%
-62.08%
-57.57%
156.9%
-51.98%
42.39%
-14.01%
-86.45%
-73.17%
--
--
--
--
--
--
--
-72.74%
25.37%
-10.37%
17.83%
40.45%
16.15%
31.06%
66.08%
10.53%
As of August 09, 2022.

Profile

Edit
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
URL https://www.nektar.com
Investor Relations URL https://ir.nektar.com/
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
XPH 10.30M USD 4.50%
HHCCX 718400.0 USD 3.86%
CNCR 971463.0 USD 3.71%
AIM25300 4.129M USD 2.85%
GOFFX 135.93M USD 2.83%
PILL 294348.0 USD 2.11%
BBP 339205.0 USD 1.97%
SMHCLX 159.00 USD 1.59%
SMHCJX 136.00 USD 1.36%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter NKTR Tweets